EdisonTV

 
VolitionRx

EdisonTV | Pharmaceutical & healthcare | 14/03/2017

Executive Interview - VolitionRx

VolitionRx (VNRX) is an international life sciences company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers. In this interview, president and CEO Cameron Reynolds discusses last week’s earnings and looks forward to forthcoming milestones for 2017. 

“2016 was a year of significant growth and advancement for Volition,” said Mr Reynolds. “The CE Mark signalled the initiation of Nu.QTM’s commercialization in the European Union and we continue to bolster our product pipeline through numerous ongoing trials. In the coming months, we expect to present the results of the full 8,000 subject data set for our Nu.QTM Colorectal Cancer Screening Triage Test as well as results from our other ongoing trials.  We also expect to announce additional trial commitments over the course of the year.”

Executive Interview - VolitionRx

Executive Interview - VolitionRx

VolitionRx (VNRX) is an international life sciences company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers. In this interview, president and CEO Cameron Reynolds discusses last week’s earnings and looks forward to forthcoming milestones for 2017.
Watch »

14/03/2017 | VolitionRx

Executive interview - Imugene

Executive interview - Imugene

Imugene is a clinical-stage immuno-oncology company. Its lead product is HER-Vaxx, a B-cell peptide vaccine for the treatment of gastric cancer. HER-Vaxx is an immuno-oncology therapy designed to treat tumours that overexpress the HER-2/neu receptor, such as breast cancer and gastric cancer. HER-Vaxx has successfully completed a Phase I study in breast cancer and has commenced a Phase Ib/II study in gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. Imugene has broadened its pipeline with the acquisition of arginine modulators (small molecules) to develop to preclinical proof of concept.
Watch »

09/03/2017 | Imugene

Executive interview - TiGenix

Executive interview - TiGenix

TiGenix is set for a decisive 2017 with possible EMA approval in H2 of the allogeneic stem cell therapy Cx601 to treat complex perianal fistulas in Crohn’s disease. This will trigger a €15m milestone from Takeda, the European partner; Takeda views Cx601 as a breakthrough therapy. A Phase I/II trial using stem cells to control severe sepsis, a major unmet need, has just started. Another interesting project is on acute cardiac stem cell therapy; Phase I/II data are expected in H117. The US IPO raised €31m net in 2016.
Watch »

07/03/2017 | TiGenix

Executive Interview - Touchstone Innovations

Executive Interview - Touchstone Innovations

Touchstone Innovations (previously Imperial Innovations) is an investment company focused on building and creating companies formed from scientific research in the ‘Golden Triangle’ (the geographical region encompassing London, Cambridge and Oxford). Touchstone has 107 companies in its portfolio, with 45 accelerated growth companies where the company actively invests or takes a seat on the board. The top 10 valued companies comprise 60.4% (£202.5m) of the total portfolio value (£335.1m as of 31 July 2016).
Watch »

05/01/2017 | Touchstone Innovations

News Announcement - VolitionRx

News Announcement - VolitionRx

Volition is a multi-national company developing simple, easy-to-use, blood-based cancer tests to accurately diagnose a range of cancers.
Watch »

03/01/2017 | VolitionRx

Executive Interview - ReNeuron

Executive Interview - ReNeuron

ReNeuron is a UK clinical-stage biotech company developing allogeneic cell-based therapies. CTX neural stem cells are in development for ischaemic stroke disability (Phase II) and critical limb ischaemia (Phase I), and human retinal progenitor cells (hRPC) are being studied for retinitis pigmentosa (Phase I/II). ReNeuron is one of the pioneers in the field of stem cells, having developed proprietary technology platforms, notably based on the CTX neural stem cell line, derived and immortalised from a single donor cell. It is developing these multipotent adult stem cells specifically for allogeneic administration (as opposed to autologous procedures). The final product can be cryopreserved, stored and transported, with a simple procedure to prepare the cells for injection, so offering a genuine off-the-shelf, cell-based therapy. There is a clear clinical and commercial appeal, in that rather than addressing the symptoms of a disease, stem cell therapy seeks to address the cause of the condition, to effect repair or reversal of the disease through the regeneration of the affected tissue.
Watch »

19/12/2016 | ReNeuron Group

Executive Interview - xBrane

Executive Interview - xBrane

Xbrane is a Swedish company focused on complex generics and biosimilars. Its leading products are Spherotide, a controlled release generic version of oncology drug Decapeptyl (sales of $0.5bn in 2015); and Xlucane, a biosimilar of Lucentis, which generated sales of $3.6bn in 2015. Xbrane has a specialised manufacturing facility for the production of Spherotide that involve a proprietary microsphere formulation. To manufacture Xlucane, the company utilises a proprietary strain of E. coli that yields 8 times more product and reduces costs by 85%. With low competition, Xbrane has a defined path to market through distribution agreements and partnering deals. The company has signed an agreement in Iran to start marketing its lead products in 2017. In China the company has recently signed an agreement for SEK87m (c $10m) to launch Spherotide in 2021. In the US and EU, Spherotide launch is expected in 2019. For Xlucane, Xbrane will conduct clinical development and registration activities during 2017-2019 with planned launch upon Lucentis patent expiration in 2020 in the US and 2022 in the EU.
Watch »

13/12/2016 | Xbrane Biopharma

Executive Interview - Abzena

Executive Interview - Abzena

Abzena (AIM:ABZA) is a UK life sciences group offering a range of services and technologies that enable its customers to develop safer and more effective biopharmaceutical products. Its core business is in its R&D service areas, which include immunology, protein engineering, ADC bioconjugation, synthetic chemistry and biomanufacturing.
Watch »

30/11/2016 | Abzena

Executive Interview - MISSION Therapeutics

Executive Interview - MISSION Therapeutics

MISSION Therapeutics, a Touchstone Innovations (AIM: IVO) investee company, is a Cambridge-based drug discovery company that is uniquely placed at the forefront of deubiquitylating enzyme (DUB) drug discovery and development. Since inception in 2011, MISSION has built and developed a proprietary chemistry platform and significant know-how in the generation of potent and selective small molecule DUB inhibitors. Ubiquitin is a small protein found in the vast majority of tissues and is involved in numerous cellular processes, including DNA damage and cell proliferation; DUBs are proteases that cleave ubiquitin from protein/other molecules. Hence targeting ubiquitin through the inhibition of DUBs holds the potential to generate novel drugs to treat cancer and other unmet medical needs, including neurodegenerative disease, inflammation, fibrosis, muscle wasting and infectious disease.
Watch »

24/11/2016 | MISSION Therapeutics

Executive Interview - Kiadis

Executive Interview - Kiadis

Kiadis Pharma is developing T cell-based therapies to address the issues associated with haematopoietic stem cell transplantation (HSCT). The company is leveraging its Theralux technology to develop ATIR101 and ATIR201 as adjunct therapies to HSCT in leukaemia and thalassemia, respectively. Kiadis's Theralux platform allows the infusion of lymphocytes from a partially matching (haploidentical) family member to the donor as it eliminates cells that could react against the host’s immune cells and cause complications such as graft vs host disease. On the back of Phase II data, Kiadis is aiming for accelerated filing of ATIR101 with the European Medicines Agency in Q117; a Phase III trial will start in H216. ATIR201 will start a Phase I/II trial in H216. Cash at end June 2016 was €23.7m, sufficient to fund operations until early 2018.
Watch »

09/11/2016 | Kiadis Pharma

Executive Interview - NetScientific

Executive Interview - NetScientific

NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board and rationalising the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in what remains of 2016 and 2017 including Series A financing for four holdings, the commercial ramp up of the Wanda digital health platform and the launch of the Vortex liquid biopsy product.
Watch »

08/11/2016 | NetScientific

Executive Interview - Crescendo

Executive Interview - Crescendo

Crescendo Biologics is a Cambridge-based, cancer-focused drug discovery and development company with a proprietary transgenic VH mouse platform and rapid formatting capabilities that are used to create its therapeutic product candidates, Humabodies. Humabodies are built from fully human single-domain antibody VH fragments (heavy chain variable domain) generated by a proprietary triple knockout transgenic mouse (Crescendo mouse) and can be bispecific or multi-specific. Its initial focus is on the development of Humabody drug conjugates (HDCs) and multi-specific checkpoint modulators.
Watch »

18/10/2016 | Crescendo

Executive Interview - PsiOxus

Executive Interview - PsiOxus

PsiOxus Therapeutics is an Oxford-based immunotherapy company that has developed a tumour-targeted delivery platform based on its lead oncolytic vaccine, Enadenotucirev (formerly ColoAd1). Enadenotucirev is an oncolytic virus that selectively kills cancer cells by lysis and is currently being studied in four clinical trials in various cancer indications. Under the PsiOxus collaboration with Bristol Myers Squibb, a Phase I combination study of Enadenotucirev with checkpoint inhibitor nivolumab (Opdivo) in a range of tumours, is due to start in Q316. PsiOxus also has a next-generation platform (T-SIGn Therapy) in development. This platform enables the anti-tumour effect of Enadenotucirev to be expanded through the addition of new genes (‘Armed EnAd’) creating a broad range of unique oncolytic immune therapeutics. NG-348, the first product candidate to emerge from this platform, will start Phase I in 2017.
Watch »

10/10/2016 | PsiOxus

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

EXTENDED Executive Interview with VolitionRX’s CEO Cameron Reynolds

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
Watch »

08/09/2016 | VolitionRx

Executive Interview - VolitionRX

Executive Interview - VolitionRX

VolitionRx (NASDAQ: VNRX), a life sciences company focused on developing diagnostic tests for cancer, announced on September 6th, that it expects to receive CE Marking on its Nu.Q Triage Colorectal Cancer Screening Test (blood test) in late 2016 and aims to begin marketing the test commencing in early 2017. The test, developed at Volition’s laboratories in Belgium in conjunction with Hvidovre Hospital, University of Copenhagen, has demonstrated the potential to reduce colonoscopies by 25% while maintaining almost 97% detection of colorectal cancer. Volition plans initially to focus its launch of the test in the EU member states, which have an aggregate screening age population of approximately 148 million persons.
Watch »

06/09/2016 | VolitionRx

Angle plc

Angle plc

Angle's proprietary Parsortix cell separation platform can be used to detect and harvest circulating tumour cells (CTCs) from blood. With its FY16 results released on 28 July, Angle delivered revenues of £361k, which represents a commercial milestone for the first ever sale of Parsortix for research use. Recently, Angle has announced results from two clinical studies carried out by its KOL partners. The initial data show that Parsortix performs as well as or better than current standard of care in detecting early-stage prostate cancer and assessing its severity and could potentially replace invasive tissue biopsy in metastatic breast cancer. Parsortix’s potential third application is for triaging women with ovarian masses before surgery, with clinical trials running in the US and Europe. In May, the company announced that the Cancer Research UK Manchester Institute is adopting Parsortix for routine research use, which will provide recurring sales. Angle raised £9.6m (net) in May, which adds safety margin to reach profitability, in our view.
Watch »

02/08/2016 | Angle

Executive Interview - ReNeuron

Executive Interview - ReNeuron

ReNeuron is a UK clinical-stage biotech company developing allogeneic cell-based therapies. CTX neural stem cells are in development for ischaemic stroke disability (Phase II) and critical limb ischaemia (Phase I) and human retinal progenitor cells (hRPC) are being studied for retinitis pigmentosa (Phase I/II). ReNeuron is one of the pioneers in the field of stem cells, having developed proprietary technology platforms, notably based on the CTX neural stem cell line, derived and immortalised from a single donor cell. It is developing these multipotent adult stem cells specifically for allogeneic administration (as opposed to autologous procedures). The final product can be cryopreserved, stored and transported, with a simple procedure to prepare the cells for injection, so offering a genuine off-the-shelf cell-based therapy. There is a clear clinical and commercial appeal in that rather than addressing the symptoms of a disease, stem cell therapy seeks to address the cause of the condition, to effect repair or reversal of the disease through the regeneration of the affected tissue. ReNeuron is funded (£65.7m in cash at 31 March 2016) to pursue pivotal studies with two cell therapy-based programmes. The company recently relocated to a new research and cell manufacturing facility in South Wales (funded by a £7.8m Welsh government grant).
Watch »

19/07/2016 | ReNeuron Group

Executive Interview - Titan Pharmaceuticals

Executive Interview - Titan Pharmaceuticals

Titan Pharmaceuticals is a speciality pharmaceutical company that has developed ProNeura, a subdermal implant that can elute a drug continuously over a six-month to one-year period. In May, the company received approval from the FDA for the first drug using this platform, Probuphine, which releases buprenorphine over six months for the treatment of opiate dependence. The US buprenorphine market is approximately $2bn and dominated with sublinqual formulations that produce less consistent blood levels of the drug and are the subject of diversion and abuse. Probuphine is commercialized by Braeburn Pharmaceuticals in the US and Canada, and Titan is entitled to $165m in sales-based milestones and tiered royalties in the mid-teens to low twenties. The company is also developing a ropinirole-eluting implant for the treatment of Parkinson’s disease and a triiodothyronine (T3) implant for the treatment of hypothyroidism, which are expected to enter the clinic in Q416 and H217 respectively.
Watch »

14/07/2016 |

Executive Interview - Mologen

Executive Interview - Mologen

Mologen is a German biotech company developing cancer immunotherapies. Its lead product is lefitolimod (MGN1703), which is being tested in a Phase III trial for metastatic colorectal cancer (mCRC) and a Phase II trial in small cell lung cancer (SCLC). Lefitolimod is also in a Phase I trial for HIV and a combination trial with Yervoy, an immune checkpoint inhibitor.
Watch »

20/04/2016 | Mologen AG

Executive Interview - Adherium

Executive Interview - Adherium

Adherium (ADR.ASX) is an ASX-listed digital health company developing technologies that address suboptimal medication use and remote patient management in chronic diseases. Adherium’s market-leading Smartinhaler platform has been independently proven to improve adherence to inhaled medications and improve health outcomes in chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). With an existing 10-year commercial product development and supply agreement with AstraZeneca (AZN) and strong relationships with other global pharmaceutical and medical technology companies and key opinion leaders (KOLs) through sales into the clinical trial sector, Adherium is positioned for strong revenue growth. The company listed on the ASX in August 2015, raising A$35m at A$0.50/share, including a US$3m investment by AZN.
Watch »

18/04/2016 |

Executive Interview - TxCell

Executive Interview - TxCell

Executive Interview - TxCell
Watch »

08/03/2016 | TxCell